Advanced Filters
noise

Beverly Hills, California Clinical Trials

A listing of Beverly Hills, California clinical trials actively recruiting patient volunteers.

Found 994 clinical trials
V Victoria Chua

Metronomic Trabectedin, Gemcitabine, and Dacarbazine for Leiomyosarcoma

This is an open label phase 2 study using metronomic doses of trabectedin, gemcitabine and dacarbazine given intravenously.

18 years of age All Phase 2
G GV20 Therapeutics

A Study of GV20-0251 in Patients With Solid Tumor Malignancies

This is a Phase 1 study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care.

18 years of age All Phase 1
V Vincent Acebo, PhD

Cannabis Effects as a Function of Sex (CanSex)

The purpose of this research is to assess the impact of cannabis on the analgesic and abuse-related effects between men and women

21 - 55 years of age All Phase 1
M Matthew B Rettig, MD

Randomized Phase II Trial of Targeted Radiation With no Castration for Mcrpc

This trial tests if the combination of comprehensive metastasis directed therapy delivered by a precision form of external beam radiotherapy (stereotactic ablative radiotherapy), combined with PSMA targeted radiopharmaceutical therapy and cessation of castration, and then followed by testosterone replacement, is an effective treatment for metastatic castration resistant prostate cancer. All …

18 years of age Male Phase 2

Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer

This phase II trial investigates how well trastuzumab deruxtecan works alone or in combination with anastrozole in treating patients with HER2 low, hormone receptor positive breast cancer. Trastuzumab deruxtecan is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug called deruxtecan. Trastuzumab attaches to HER2 expressed at low levels …

18 years of age All Phase 2
L Linda Roan, MS

Therapies for Down Syndrome Regression Disorder

Individuals with Down syndrome (DS) have an increased risk of numerous co-occurring conditions, including the neuropsychiatric condition known as Down Syndrome Regression Disorder (DSRD). A DSRD diagnosis often includes a sub-acute onset of catatonia, mutism, depersonalization, loss of ability to perform activities of daily living, hallucinations, delusions, and aggression and …

8 - 30 years of age All Phase 2
R Rhona Littman

Coronary Atherosclerosis T1-Weighted Characterization (CATCH)

This study proposes to develop an MRI technique named Coronary Atherosclerosis T1-weighed Characterization (CATCH) that will improve the quality and reliability of coronary atherosclerosis evaluation, as well as simplify the scanning process and significantly shorten imaging time compared with conventional imaging methods.

18 years of age All Phase N/A
D Daniel Zlotoff, Dr.

Abatacept in Immune Checkpoint Inhibitor Myocarditis

The primary aim is to test whether abatacept, as compared to placebo, is associated with a reduction in major adverse cardiac events (MACE) among participants hospitalized with myocarditis secondary to an immune checkpoint inhibitor (ICI). The primary outcome, MACE, is a composite of first occurrence of cardiovascular death, non-fatal sudden …

18 years of age All Phase 3
S Samira Torna, BS

Resources, Inspiration, Support and Empowerment (RISE) for Black Pregnant Women

Perinatal Mood and Anxiety Disorders (PMADs) encompass a range of mental health disorders that occur during pregnancy and up to one year postpartum. Approximately 13% of women experience PMADs. This rate doubles for those with adverse perinatal outcomes (APO) and triples in Black women. Recent research points to racism as …

18 - 65 years of age Female Phase 2/3
V Vivian Hwe

Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease

This phase 2 multicenter, open-label clinical trial will evaluate safety and efficacy of 4 weeks of oral seliciclib in patients with newly diagnosed, persistent, or recurrent Cushing disease. Funding Source - FDA Office of Orphan Products Development (OOPD)

18 years of age All Phase 2

Simplify language using AI